Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 125,990

Document Document Title
WO/2017/072335A1
The present invention relates to a mast cell inhibitor, a pharmaceutical composition and a method for the treatment of patients afflicted with Parkinson's disease, wherein said patients are treated with a tyrosine kinase inhibitor or mas...  
WO/2017/070796A1
The present application relates to novel heterocycle derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chronic n...  
WO/2017/072219A1
The invention relates to a nutritional or therapeutic agent which includes a mixture of molecules obtained from Vitis vinifera and Vaccinium angustifolium , including: at least 1 % of catechins and epicatechins, given as a percentage by ...  
WO/2017/069662A1
An agent exhibiting anti-stress, anxiolytic and anti-depression activity, and a composition based thereon. The invention relates to the field of pharmaceutical science, and specifically to chemical compounds based on lithium salts, and p...  
WO/2017/068069A1
The invention relates to a composition comprising a mixture of at least three molecules: a mono-caffeoylquinic acid, a di-caffeoylquinic acid and oleuropein. Said composition is particularly used as a medicament or a nutrition product fo...  
WO/2017/068070A1
The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeutics to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also a...  
WO/2017/070573A1
Optogenetic and chemogenetic actuators are critical for deconstructing the neural correlates of behavior. However, these tools have several drawbacks, including invasive modes of stimulation or slow on/off kinetics. These disadvantages h...  
WO/2017/070068A1
The invention provides a crystalline form of 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hyd roxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl ]ethanone, and pharmaceutical compositions thereof. The invention furt...  
WO/2017/068583A1
A method of treating a neurodegenerative disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a CXCR4 antagonist and lactate or/and zinc. Kits for treating same are also disclosed.  
WO/2017/068089A9
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a l...  
WO/2017/068057A1
The invention relates to a composition comprising at least a mixture of molecules extracted from Chrysanthellum indicum, Cynara scolymus and Lycium barbarum. This composition is in particular useful as a nutritional product or health pro...  
WO/2017/068090A1
The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in ...  
WO/2017/070293A1
The present disclosure relates to pharmaceutical compositions comprising an effective amount of L-dopa and an effective amount of a phosphodiesterase 9 inhibitor, and methods for treating Parkinson's disease or Parkinsonism, comprising a...  
WO/2017/069279A1
Provided is a compound that has an effect of inhibiting RIP1 kinase and is useful as a prophylactic or therapeutic agent for Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiples sclerosis, chronic nephropathy, a...  
WO/2017/069182A1
The purpose of the present invention is to provide a vaccine that can simultaneously reduce Aβ deposition and tau deposition in the brain by means of a single molecule. The present invention provides a recombinant vector comprising DNA ...  
WO/2017/068089A3
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a l...  
WO/2017/068388A3
The present invention relates to the use of the synthetic PnTx-19 peptide for preparing analgesic medicinal drugs for the treatment of patients suffering from neuropathic pain, nociceptive pain (sensitisation of nociceptors by prostaglan...  
WO/2017/069270A1
Provided is a novel compound or a pharmaceutically acceptable salt thereof that is useful for treating or preventing, on the basis of the PAM effects of the GABAB receptor, diseases such as autism spectrum disorder, fragile X syndrome, s...  
WO/2017/067870A1
The present invention relates to a pharmaceutical composition comprising a combination of trazodone or a salt thereof, and gabapentin or a salt or prodrug thereof, said combination having a synergistic effect in the treatment of pain.  
WO/2017/070589A1
Disclosed herein are compositions and methods for the diagnosis and treatment of CNS autoimmune diseases such as MS. The methods of treatment may include administering to the subject at least one of an LTβR inhibitor, a CXCR2 inhibitor,...  
WO/2017/069980A1
The present invention relates to novel aminoisoxazoline compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, an...  
WO/2017/067527A1
The present invention relates to a benzobicyclon compound as presented in formula (I) or pharmaceutically acceptable salts thereof. Also disclosed are a preparation method for said compound, pharmaceutical compositions containing the ben...  
WO/2017/070525A1
In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise adminis...  
WO/2017/069275A1
The present invention provides a novel compound having excellent inhibitory action against KAT II, a production method therefor, a use therefor, and a pharmaceutical composition, or the like, that includes the compound. Provided is the c...  
WO/2017/069226A1
A compound represented by general formula [I] (in the formula, X represents N or the like, Y represents CH or the like, RA represents an optionally substituted cycloalkyl group or the like, R1 represents an alkyl group or the like, R2 re...  
WO/2017/069173A1
Provided is a compound that has cholinergic muscarinic M1 receptor positive allosteric modulator activity and is useful as a medicine, e.g., a preventative or treatment agent for Alzheimer's disease, schizophrenia, pain, sleep disorders,...  
WO/2017/066368A1
The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMD A) receptor and thereby making them useful for the treatment...  
WO/2017/064512A1
Anti-angiogenic treatments, for example treatment of ocular neovascularization or cancer, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of treating or preve...  
WO/2017/066421A1
Provided are methods of treating cognitive impairment and/or psychosis and/or movement disorders by administering a pharmaceutical composition of eplivanserin or a pharmaceutically acceptable salt thereof to a subject in need thereof.  
WO/2017/066747A1
Methods and compositions for treating gastrointestinal inflammation in a subject are provided.  
WO/2017/064488A1
The disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof: The disclosure also provides processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing th...  
WO/2017/066626A1
The disclosure provides an injectable neurosteroid nanoparticle formulation comprising nanoparticles having a D50 of less than 2000 nm the nanoparticles comprising a neurosteroid of Formula I, where the variables R1-R9 and X are defined ...  
WO/2017/064688A1
The present invention offers an effective alternative method for treating neurological disorders, preferably those induced by a nerve injury or by a neurodegenerative process. The present invention is the first to show that a substantial...  
WO/2017/066366A1
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various ...  
WO/2017/066488A1
Provided herein are methods and compositions for effective treatment or prevention of pain, which also reduce or eliminate adverse effects associated with an opioid analgesic. In addition, provided herein are methods and compositions for...  
WO/2017/066590A1
This disclosure features combinations of NMDA modulators and atypical antipsychotics. The disclosure provides for example, methods of treating schizophrenia, bipolar disorder, and/or cognitive impairment disorder in a patient in need the...  
WO/2017/066444A1
Methods for treating learning disabilities associated with fetal alcohol syndrome and other neurological disorders by administering SK channel blockers, antagonists, inhibitors or modifiers like tamapin.  
WO/2017/064876A1
Provided is a prophylactic and therapeutic agent for Rett syndrome (RTT). A medicinal composition that comprises ghrelin and a pharmacologically acceptable carrier; and a prophylactic and therapeutic agent for RTT that comprises a therap...  
WO/2017/064098A1
The present invention relates to the use of naltrexone for the manufacture of a medicament for the treatment of somatoform pain disorder or persistent pain disorder. The medication is characterized by significant reduction of the symptoms.  
WO/2017/065314A1
The present invention pertains to a method for producing a royal jelly fraction, the method including eluting royal jelly in water and obtaining a residue, eluting the resulting residue in 50% ethanol and obtaining a residue, then elutin...  
WO/2017/063581A1
Provided is an oral preparation for cardiovascular diseases containing a compound 1, wherein the oral preparation is prepared into a large tablet by means of a dry granulation process, the large tablet comprises the compound 1, a filler,...  
WO/2017/066729A1
Provided are novel methods for the treatment or prophylaxis of pain in a feline in need thereof comprising administering to the feline an effective amount of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically accep...  
WO/2017/065602A1
The disclosure provides novel methods of treating neuromuscular or neurologic disease, for example, Amyotrophic lateral sclerosis (ALS), through reducing GABAergic and Glycinergic inhibitory neurotransmitter activity overstimulation. Pha...  
WO/2017/066730A1
Provided are novel methods for the treatment or prophylaxis of pain in an equine in need thereof comprising administering to the equine an effective amount of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acce...  
WO/2017/066204A1
The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-bin...  
WO/2017/060870A1
The present invention relates to new combinations of treatments for abnormal dopamine deficiency disorders, and related conditions, comprising deuterated catecholamine derivatives and catechol-O-methyltransferase (COMT) inhibitors.  
WO/2017/062875A1
Compositions and methods for administration of local anesthetics that are delivered by a single injection and enable repeated on-demand or high influx analgesia over extended periods have been developed. Pharmaceutical compositions inclu...  
WO/2017/062974A1
Provided are methods for treatment and prevention of ischemia- reperfusion injury and chronic intermittent hypoxia related injury through administering a neuroprotective compound. A subject benefiting from the method of the invention may...  
WO/2017/060530A1
The invention relates to compounds of formula (I), particularly for the use thereof as a medicament, especially in the treatment or prevention of neurogenerative disorders. The invention also relates to the methods for producing said com...  
WO/2017/062657A1
Methods and compositions for treating traumatic brain injury. The methods and compositions utilize a multi-functional oxygen reactive polymer (ORP) that includes repeating units that include a reactive oxygen species (ROS) scavenging gro...  

Matches 551 - 600 out of 125,990